Table 1.
Clinical characteristics and laboratory values of study participants by BP categories.
Table 2.
Clinical characteristics and laboratory values of study participants in normotensive and hypertension with/without TOD.
Table 3.
Clinical characteristics and laboratory values of study participants with and without serologic evidence of CMV infection.
Fig 1.
Incidence of hypertension and hypertensive TOD with different CMV IgG titers in study participants.
Abbreviations: TOD, target organ damage; CMV, cytomegalovirus. A. Incidence of hypertension with different CMV IgG titers in all study participants. B. Incidence of hypertensive TOD with different CMV IgG titers in participants with hypertension.
Table 4.
Correlation of CMV IgG titers with BP in study participants.
Table 5.
Correlation between CMV IgG titers and the different stages of BP and hypertension and hypertension without/with TOD in study participants.
Table 6.
Hazard ratio for incidence of hypertension by CMV IgG titers.
Table 7.
Hazard ratio for incidence of different grades hypertension by CMV IgG titers.
Table 8.
Hazard ratio for incidence of hypertension with TOD by CMV IgG titers.
Table 9.
Correlation of CMV IgG titers with the levels of inflammatory cytokines.
Table 10.
Correlation of the levels of inflammatory cytokines with BP.
Table 11.
Correlation between the levels of inflammatory cytokines and the different stages of BP and hypertension and hypertension without/with TOD in study participants.
Table 12.
Hazard ratio for incidence of hypertension by the levels of inflammatory cytokines.
Table 13.
Hazard ratio for incidence of different grades hypertension by the levels of inflammatory cytokines.
Table 14.
Hazard ratio for incidence of hypertension with TOD by the levels of inflammatory cytokines.